5th February 2020
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs was notified that on the 24th January 2020, David Tapolczay, Non-Executive Chairman of the Group, sold 650,000 Ordinary Shares (“Ordinary Shares”) in the Group at a price of 8.7p per share. Download News